WVE Stock Wave Life Sciences, Inc.
ACCUMULATE US · NasdaqGMRecent insider buying and multiple RNA catalysts position shares for re-rating.
Signal breakdown
- ▸Insider buying after share offering and catalyst pipeline.
- ▾Below 50-day MA (-23.58%)
- ▾Near 52-week low (0.9% of range)
Is WVE a buy right now?
Trend: WVE is trading below the 50-day average (-23.57%), RSI 40 — neutral momentum, with a 3-month return of -45.50%.
Valuation & quality: Wave Life Sciences, Inc. trades on forward P/E -2.8, price-to-book 1.37; fundamentals show net margin 0.0%, return on equity -67.4%, revenue growth -73.9% year on year.
Analyst consensus: 19 analysts have a mean 12-month price target of $17.68 (+450.9% vs the last close; range $10.00 – $42.00), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — Recent insider buying and multiple RNA catalysts position shares for re-rating.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -48.00% | -2.60% | -6.80% | -11.70% | -5.20% | -11.10% | -24.50% | -13.20% |
Fundamentals
Analyst price target
Technical signals
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health.
Sector: Healthcare · Industry: Biotechnology · United States · 317 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.